Aventis Diabetes Outlook: Lantus Has Brighter Future Than Exubera, Firm Says

Aventis expects the long-acting insulin Lantus will be a bigger product than Exubera (inhaled insulin) in the diabetes market, Management Board Chairman Igor Landau maintained

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet